GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » FCF Yield %

Perspective Therapeutics (Perspective Therapeutics) FCF Yield % : -3.70 (As of May. 11, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Perspective Therapeutics's Trailing 12-Month Free Cash Flow is $-37.99 Mil, and Market Cap is $1,027.10 Mil. Therefore, Perspective Therapeutics's FCF Yield % for today is -3.70%.

The historical rank and industry rank for Perspective Therapeutics's FCF Yield % or its related term are showing as below:

CATX' s FCF Yield % Range Over the Past 10 Years
Min: -50.46   Med: -13.12   Max: -1.64
Current: -3.7


During the past 13 years, the highest FCF Yield % of Perspective Therapeutics was -1.64%. The lowest was -50.46%. And the median was -13.12%.

CATX's FCF Yield % is ranked worse than
52.83% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: -2.63 vs CATX: -3.70

Perspective Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 173.64%.


Perspective Therapeutics FCF Yield % Historical Data

The historical data trend for Perspective Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics FCF Yield % Chart

Perspective Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.88 -10.23 -2.84 -18.17 -33.53

Perspective Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.94 -22.33 -18.42 -53.84 -32.12

Competitive Comparison of Perspective Therapeutics's FCF Yield %

For the Medical Devices subindustry, Perspective Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics's FCF Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's FCF Yield % falls into.



Perspective Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Perspective Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-37.985 / 113.28762
=-33.53%

Perspective Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-9.097 * 4 / 113.28762
=-32.12%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perspective Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Perspective Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics (Perspective Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Hills Street, Suite 106, Richland, WA, USA, 99354
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.
Executives
Williamson Robert F Iii director 140 LASALLE AVENUE, PIEDMONT CA 94610
Markus Puhlmann officer: Chief Medical Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Jonathan Robert Hunt officer: Chief Financial Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Lori A Woods officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Johan M. Spoor director, officer: CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Mark John Austin officer: Controller/Prin Fin&Acct Offic 350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale director 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick director 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann director 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon officer: VP of Sales & Marketing 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline officer: Dir. of Operations, Secretary 350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter officer: VP of Human Resources 350 HILLS STREET SUITE 106, RICHLAND WA 99354